运甲状腺素蛋白淀粉样变性治疗市场 - 按类型、疾病类型、药物类型、给药途径、配销通路- 全球预测 2024 - 2032

在医学研究和技术进步的推动下，转甲状腺素蛋白淀粉样变性治疗市场规模预计 2024 年至 2032 年间复合年增长率为 7.5%。最近，一些治疗创新在阻止疾病进展和改善患者预后方面提供了有希望的结果。转甲状腺素蛋白淀粉样变性的认识和诊断率不断提高，特别是在人口老化地区，将有助于市场扩张。例如，全球范围内发生的遗传性转甲状腺素蛋白介导的 (hATTR) 可能会影响约 50,000 人，根据受影响的器官表现出不同的症状。

此外，製药公司和研究机构之间也开展了合作，透过利用综合专业知识和资源来加速发现过程，从而促进新药和疗法的开发。越来越多的监管部门批准新疗法以及转甲状腺素蛋白淀粉样变性疗法报销范围的扩大将进一步提高治疗选择的可及性。

转甲状腺素蛋白淀粉样变性治疗产业分为类型、疾病类型、药物类型、给药途径、配销通路、区域。

就给药途径而言，由于将治疗剂直接输送到血流中的功效和便利性，2024年至2032年期间肠胃外细分市场的市场规模预计将达到7.8%的复合年增长率。肠胃外方法确保药物吸收快速且一致，避免了与口服给药相关的胃肠道降解和变异性。对于经常出现胃肠道症状和吸收不良问题的转甲状腺素蛋白淀粉样变性患者来说，肠胃外给药提供了有效递送治疗药物的可靠方法。

根据配销通路，到2032 年，线上药局领域的转甲状腺素蛋白淀粉样变性治疗市场将录得8% 的成长率。转甲状腺素蛋白淀粉样变性的药物他们的家。这种便利性对于居住在偏远地区的患者和行动不便的患者特别有利，他们可能在进入传统实体药局时面临挑战。

到 2032 年，欧洲转甲状腺素蛋白淀粉样变性治疗市场规模将呈现 7.8% 的复合年增长率，这归因于对医疗基础设施和专注于罕见疾病的研究计划的投资不断增加。欧洲国家正在优先考虑医疗保健的进步，并分配大量资源来支持创新疗法和治疗方式。此外，监管机构还实施了加速审批途径和激励措施，以鼓励孤儿药的开发，进一步刺激了区域产业的扩张。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 转甲状腺素蛋白淀粉样变性病例盛行率增加
    • 新疗法的开发
    • 老年人口不断增加
    • 诊断技术的进步
  • 产业陷阱与挑战
    • 治疗选择有限
    • 治疗费用高
• 成长潜力分析
• 监管环境
• 管道分析
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按类型，2018 - 2032

• 主要趋势
• ATTR 淀粉样变性伴随多发性神经病变 (ATTR-PN)
• ATTR 淀粉样变性伴随心肌病变 (ATTR-CM)

第 6 章：市场估计与预测：按疾病类型，2018 - 2032

• 主要趋势
• 遗传性转甲状腺素蛋白淀粉样变性
  • 多发性神经病变
  • 心肌病变
  • 混合型
• 野生型转甲状腺素蛋白淀粉样变性

第 7 章：市场估计与预测：按药物类型，2018 - 2032

• 主要趋势
• 塔法米迪斯
• 派蒂西兰
• 伊诺特森
• 其他药物类型

第 8 章：市场估计与预测：按管理途径，2018 年 - 2032 年

• 主要趋势
• 口服
• 注射用

第 9 章：市场估计与预测：按配销通路划分，2018 年 - 2032 年

• 主要趋势
• 医院药房
• 零售药局
• 网路药房

第 10 章：市场估计与预测：按地区，2018 - 2032

• 主要动向：按地区
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 中东和非洲其他地区

第 11 章：公司简介

• Acrotech Biopharma, LLC
• Alnylam Pharmaceuticals, Inc.
• AstraZeneca PLC
• Astellas Pharma Inc.
• BridgeBio Pharma, Inc.
• Bristol-Myers Squibb Company
• Ionis Pharmaceuticals, Inc.
• Johnson & Johnson
• Prothena Biosciences Limited
• Pfizer Inc.
• SOM Innovation Biotech, S.L.

Transthyretin amyloidosis treatment market size is expected to witness 7.5% CAGR between 2024 and 2032, driven by the advancements in medical research and technologies. Lately, several therapeutic innovations are offering promising outcomes in halting disease progression and improving patient outcomes. The increasing awareness and diagnosis rate of transthyretin amyloidosis, particularly in regions with aging population will contribute to the market expansion. For instance, the worldwide occurrence of hereditary transthyretin-mediated (hATTR) is likely to affect roughly 50,000 individuals, showcasing diverse symptoms depending on the organs affected.

Moreover, there have also been collaborations between pharmaceutical companies and research institutions to facilitate the development of new drugs and therapies by leveraging combined expertise and resources to accelerate the discovery process. Growing regulatory approvals for novel treatments and the expansion of reimbursement coverage for transthyretin amyloidosis therapies will further enhance the accessibility of treatment options.

The transthyretin amyloidosis treatment industry is divided into type, disease type, drug type, route of administration, distribution channel, and region.

With respect to route of administration, the market size from the parenteral segment is slated to depict 7.8% CAGR between 2024 to 2032, due to the efficacy and convenience in delivering therapeutic agents directly into the bloodstream. Parenteral method ensures rapid and consistent drug absorption, bypassing gastrointestinal degradation and variability associated with oral administration. For patients with transthyretin amyloidosis, who often experience gastrointestinal symptoms and malabsorption issues, parenteral administration offers a reliable means of delivering therapeutic agents effectively.

Based on distribution channel, the transthyretin amyloidosis treatment market from the online pharmacy segment will record 8% growth rate through 2032. These channels provide a convenient platform for individuals to purchase prescription medications and specialty treatments, including those for transthyretin amyloidosis, from the comfort of their homes. This accessibility is particularly beneficial for patients residing in remote areas and those with mobility limitations, who may face challenges accessing traditional brick-and-mortar pharmacies.

Europe transthyretin amyloidosis treatment market size will exhibit 7.8% CAGR through 2032, attributed to increasing investments in healthcare infrastructure and research initiatives focused on rare diseases. European countries are prioritizing healthcare advancements and allocating substantial resources to support innovative therapies and treatment modalities. Additionally, regulatory agencies have implemented expedited approval pathways and incentives to encourage the development of orphan drugs, further stimulating the regional industry expansion.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of transthyretin amyloidosis cases
    • 3.2.1.2 Development of novel therapies
    • 3.2.1.3 Rising geriatric population
    • 3.2.1.4 Advancements in diagnostics techniques
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Limited treatment options
    • 3.2.2.2 High cost of treatment
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
  • 3.6.1 Supplier power
  • 3.6.2 Buyer power
  • 3.6.3 Threat of new entrants
  • 3.6.4 Threat of substitutes
  • 3.6.5 Industry rivalry
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 ATTR amyloidosis with polyneuropathy (ATTR-PN)
• 5.3 ATTR amyloidosis with cardiomyopathy (ATTR-CM)

Chapter 6 Market Estimates and Forecast, By Disease Type, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Hereditary transthyretin amyloidosis
  • 6.2.1 Polyneuropathy
  • 6.2.2 Cardiomyopathy
  • 6.2.3 Mixed type
• 6.3 Wild type transthyretin amyloidosis

Chapter 7 Market Estimates and Forecast, By Drug type, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Tafamidis
• 7.3 Patisiran
• 7.4 Inotersen
• 7.5 Other drug types

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Oral
• 8.3 Parenteral

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Hospital pharmacy
• 9.3 Retail drug stores
• 9.4 Online pharmacy

Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 10.1 Key trends, by region
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Acrotech Biopharma, LLC
• 11.2 Alnylam Pharmaceuticals, Inc.
• 11.3 AstraZeneca PLC
• 11.4 Astellas Pharma Inc.
• 11.5 BridgeBio Pharma, Inc.
• 11.6 Bristol-Myers Squibb Company
• 11.7 Ionis Pharmaceuticals, Inc.
• 11.8 Johnson & Johnson
• 11.9 Prothena Biosciences Limited
• 11.10 Pfizer Inc.
• 11.11 SOM Innovation Biotech, S.L.